Plasma exchange therapy for acute necrotizing encephalopathy of childhood

Kechun Li | Tao Zhang | Gang Liu | Ping Jin | Yeqing Wang | Lijie Wang | Meixian Xu | Chunyi Liu | Yeqing Wang | Lijie Wang | Meixian Xu | Chunyi Liu | Suyun Qian

1Department of Pediatric Intensive Care Unit, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China
2Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
3Department of Pediatric Intensive Care Unit, Hebei Children’s Hospital, Hebei Medical University, Shijiazhuang, Hebei, China
4Department of Pediatric Intensive Care Unit, Bao’an Maternity & Child Health Hospital, Shenzhen, Guangdong, China
5Research Unit of Critical infection in Children, Chinese Academy of Medical Sciences, 2019RU016

Correspondence
Suyun Qian, Department of Pediatric Intensive Care Unit, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Email: syqian1211@163.com
Chunfeng Liu, Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
Email: zhliu258@hotmail.com

Funding source
This study was supported by Capital’s Funds for Health Improvement and Research of Beijing Children’s Hospital, Capital Medical University (No. 2020-2-2094) and the CAMS Innovation Fund for Medical Sciences (No. 2019-I2M-5-026).

Received: 8 April, 2021
Accepted: 20 May, 2021

ABSTRACT
Importance: Acute necrotizing encephalopathy (ANE) is a rare disease with high mortality. Plasma exchange (PLEX) has recently been reported to treat ANE of childhood (ANEC), but its efficacy is uncertain.

Objective: This study aimed to investigate the effectiveness of PLEX on ANEC.

Methods: A retrospective study was conducted in four pediatric intensive care units from December 2014 to December 2020. All patients who were diagnosed with ANEC were included; however, these patients were excluded if their length of stay was less than 24 h. Participants were classified into PLEX and non-PLEX groups.

Results: Twenty-nine patients with ANEC were identified, 10 in the PLEX group and 19 in the non-PLEX group. In the PLEX group, C-reactive protein, procalcitonin, alanine aminotransferase, and aspartate aminotransaminase levels were significantly lower after 3 days of treatment than before treatment (13.1 vs. 8.0, P = 0.043; 9.8 vs. 1.5, P = 0.028; 133.4 vs. 31.9, P = 0.028; 282.4 vs. 50.5, P = 0.046, respectively). Nine patients (31.0%, 9/29) died at discharge, and a significantly difference was found between the PLEX group and non-PLEX group [0 vs. 47.4% (9/19), P = 0.011]. The median follow-up period was 27 months, and three patients were lost to follow-up. Thirteen patients (50.0%, 13/26) died at the last follow-up, comprising three (33.3%, 3/9) in the PLEX group and ten (58.8%, 10/17) in the non-PLEX group, but there was no significant difference between the two groups (P = 0.411). Three patients (10.3%, 3/29) fully recovered.

Interpretation: PLEX may reduce serum C-reactive protein and procalcitonin levels and improve liver function in the short term. PLEX may improve the prognosis of ANEC, and further studies are needed.

KEYWORDS
Acute necrotizing encephalopathy, Children, Plasma exchange, Prognosis
INTRODUCTION

Acute necrotizing encephalopathy (ANE) is a distinctive type of acute encephalopathy with rapid progression of brain dysfunction and a disastrous outcome.\(^1\) ANE mainly occurs in children, especially those with an influenza virus infection,\(^2\) and which could be an important cause of death or disability due to a critical influenza infection. Cytokine storm,\(^3\) hereditary susceptibility,\(^4\) immune etiology,\(^5\) and other unknown factors are related to ANE pathogenesis. The prognosis of ANE was poor. The mortality of ANE was around 30%, and only 10% of patients fully recovered.\(^2,3,5\)

A unified treatment schedule for acute necrotizing encephalopathy of childhood (ANECC) has not been established. Steroids and intravenous immunoglobulin (IVIG) for immunomodulation therapy are the most commonly used drugs to treat ANECC,\(^6,7,9,12,17\) and early steroid pulse therapy has been recommended.\(^14\) Moreover, plasma exchange (PLEX) has recently been reported for some ANECC patients, which could be an effective treatment to remove inflammatory mediators and other harmful substances that are caused by ANECC, but the outcome has been variable.\(^9,15,16\) In this study, a multicenter retrospective study was conducted at four pediatric intensive care units (PICUs) in China, and it aimed to investigate the efficacy of PLEX therapy in treating ANECC.

METHODS

Ethical approval

The study protocol was reviewed and approved by the Institutional Review Board for Beijing Children’s Hospital, Capital Medical University (approval number: 2019-k-384), with waiver of the requirement for informed consent.

Patients

This retrospective study was conducted at four PICUs from December 2014 to December 2020. The four participating centers were Beijing Children’s Hospital, Capital Medical University (Beijing, China), Shengjing Hospital of China Medical University (Shenyang, China), Hebei Children’s Hospital affiliated to Hebei Medical University (Shijiazhuang, China), and Bao’an Maternity & Child Health Hospital (Shenzhen, China), respectively.

The inclusion criteria for ANECC were as follows: 1) all patients were 29 days to 18 years old; 2) acute encephalopathy followed by a febrile disease, with rapid deterioration of consciousness and convulsions; 3) commonly increased cerebrospinal fluid (CSF) protein without pleocytosis, and elevated serum aminotransferases with variable degrees, but no hyperammonemia; 4) cranial imaging showing symmetric and multifocal brain lesions with involvement of bilateral thalami, and possible involvement of cerebral periventricular white matter, internal capsule, putamen, upper brain stem tegmentum, and cerebellar medulla; and 5) exclusion of similar diseases.\(^5\) PLEX is a complex invasive treatment, and patients whose length of stay was less than 24 h were excluded to allow better observation of PLEX efficacy in treating ANECC. The participants were classified into PLEX and non-PLEX groups.

Data collection

The demographics, clinical manifestations, laboratory examination results, therapeutic schedules, and clinical outcomes were collected. The demographic information included age, sex, family history, and underlying diseases. Clinical manifestations included symptoms, Glasgow coma scale score (GCS), and ANE severity score (ANE-SS)\(^17\) on admission. Laboratory examination results including serum C-reactive protein (CRP) and procalcitonin (PCT) levels, routine blood test results, and liver enzyme levels were collected when patients were admitted to the PICU and 3 days after treatment. The results of routine CSF, cranial imaging, and etiology (respiratory virus antigen or nucleic acid detection) tests were also collected. The therapeutic schedules included the main drugs that were administered after hospitalization in the PICU. Follow-up was performed by telephone interview or outpatient service to evaluate the neurological function in surviving children with pediatric cerebral performance category scale (PCPC) and pediatric overall performance category scale (POPC).

Statistical analysis

Continuous variables were expressed as the mean ± standard deviation or as the median (interquartile range) depending on whether the data were parametric or nonparametric. Categorical variables were expressed as numbers and percentages. A student’s t-test was used for parametric variables and Mann–Whitney U test was used for nonparametric continuous variables. Categorical variables were analyzed using Fisher’s test. The Wilcoxon test was used to identify differences for the same variables at different times. All analysis was conducted using SPSS statistical software version 24 (IBM, Armonk, NY). A two-sided P value < 0.05 was considered to be statistically significant.

RESULTS

Fifty-one children with ANE were eligible for this study, and 29 patients were identified, 10 in the PLEX group and 19 in the non-PLEX group (Figure 1). Table 1 shows the characteristics of all the ANEC patients. The median onset age was 30 months. Thirteen patients were males, and the male-to-female ratio was 1:1.2. Winter was the most common season. One patient had idiopathic uveitis, and began to take cyclosporine and methylprednisolone
Tablets orally 5 months before admission. The median time from disturbance of consciousness to admission was 24 h. During the acute phase, fever, convulsion, and disturbance of consciousness were the most common presentations.

**TABLE 1** Clinical characteristics of children with acute necrotizing encephalopathy

| Variables                                      | Data          |
|------------------------------------------------|---------------|
| **Basic information**                         |               |
| Age (months)                                  | 30 (19, 46)   |
| Gender (male)                                 | 13 (44.8)     |
| Season onset (winter)                         | 18 (62.1)     |
| Underlying disease                            | 11 (3.4)      |
| From disturbance of consciousness to admission to PICU (hours) | 24 (10, 60) |
| **Symptoms**                                  |               |
| Fever                                         | 29 (100)      |
| Convulsion                                    | 29 (100)      |
| Disturbance of consciousness                  | 29 (100)      |
| Cough                                         | 16 (55.2)     |
| Vomiting                                      | 13 (44.8)     |
| Shock                                         | 18 (27.6)     |
| Diarrhea                                      | 17 (24.1)     |

Data are presented as n (%) or median (lower quartile, upper quartile).

Table 2 shows that there are no significant differences between the two groups for GCS and ANE-SS when patients were admitted to the PICU. Most patients had elevated CRP (58.6%, 17/29) and PCT (82.8%, 24/29) levels on admission. Although the median CRP and PCT levels were higher in the PLEX group than in the non-PLEX group, the differences were not significant. Most patients had elevated alanine aminotransferase (ALT; 62.1%, 18/29) and aspartate aminotransaminase (AST; 75.9%, 22/29) levels on admission. The median ALT and AST levels were higher in the PLEX group than in the non-PLEX group, and a significant difference was found in AST between the two groups (355.1 vs. 74.0, P = 0.039). The routine CSF results were similar in both groups. The most common pathogen was the influenza virus (77.8%, 14/18). Cranial imaging results showed that bilateral thalami were involved in all patients, and most of them had lesions in the cerebral periventricular white matter (58.6%, 17/29) and internal capsule (51.7%, 15/29). The brainstem was involved in 14 patients (48.3%, 14/29).

Laboratory examination results 3 days after treatment were collected in 18 patients (62.1%, 18/29), seven in the PLEX group and eleven in the non-PLEX group.
The pre- and post-treatment indicators in the two groups were compared, and the results are shown in Table 3. In the PLEX group, CRP and PCT levels were significantly lower after comparing with before treatment (CRP: 13.1 vs. 8.0, \( P = 0.043 \); PCT: 9.8 vs. 1.5, \( P = 0.028 \)). ALT and AST levels were also significantly lower after comparing with before treatment in the PLEX group (ALT: 133.4 vs. 31.9, \( P = 0.028 \); AST: 282.4 vs. 50.5, \( P = 0.046 \)). In the non-PLEX group, only the CRP level was significantly lower after comparing with before treatment (19.0 vs. 5.3, \( P = 0.038 \)).

Most patients (75.9%, 22/29) required invasive mechanical ventilation. The median duration of mechanical ventilation was longer in the PLEX group than the non-PLEX group, but the difference was not significant (Table 4). Most patients received steroids (96.6%, 28/29), IVIG (96.6%, 28/29), and antiviral therapy (93.1%, 27/29). The period from disturbance of consciousness to the first cycle of PLEX ranged from 6 h to 78 h, with a median of 32 h. The first cycle of PLEX was performed in eight patients (80%, 8/10) within 24 h after the patients were admitted to the PICU, but two patients received PLEX from 48 h to 72 h after admission due to a poor response to immunomodulation therapy.

Nine patients (31.0%, 9/29) died a short time after admission. All the dead patients were in the non-PLEX group, and a significant difference was found between the PLEX group and non-PLEX group at discharge (0 vs. 47.4% (9/19), \( P = 0.011 \) (Table 4). Considering the economic and prognostic factors, eight patients (27.6%, 8/29) chose palliative treatment. The follow-up period ranged from 2 months to 60 months, and the median period was 27 months. Three patients were lost to follow-up, and thirteen patients (50.0%, 13/26) died at the last follow-up.

**TABLE 2** Laboratory findings of children with acute necrotizing encephalopathy in the two study groups

| Variables                      | Plasma exchange group (n = 10) | Non-plasma exchange group (n = 19) | \( P \) |
|--------------------------------|--------------------------------|------------------------------------|-------|
| Severity of illness on admission | GCS                            | 6 (6.8)                            | 6 (3.7) | 0.310 |
|                                | ANE-SS                         | 2 (1.3)                            | 2 (0.5) | 0.926 |
| Laboratory findings on admission | Serum CRP (mg/L)                | 16.1 (7.8, 26.1)                   | 11.0 (8.0, 37.0) | 0.817 |
|                                | Serum PCT (ng/mL)               | 12.6 (6.9, 51.9)                   | 5.5 (0.2, 44.0) | 0.281 |
|                                | WBC (\( \times 10^9/L \))       | 6.7 (3.3, 9.4)                     | 5.5 (3.5, 7.1) | 0.680 |
|                                | PLT < 100 (\( \times 10^9/L \)) | 4 (40.0)                           | 4 (21.1)  | 0.390 |
|                                | ALT (U/L)                       | 139.0 (60.0, 976.5)                | 31.9 (13.0, 180.0) | 0.060 |
|                                | AST (U/L)                       | 355.1 (135.7, 1414.4)              | 74.0 (31.7, 408.0) | 0.039 |
|                                | Blood ammonia (mmol/L)          | 34.0 (18.5, 41.1)                  | 46.0 (31.5, 56.7) | 0.125 |
|                                | CSF routine                     |                                    |         |       |
|                                | Cell counts (\( \times 10^9/L \)) | 2.0 (0.4, 8.8)                  | 2.0 (1.0, 2.0) | 0.962 |
|                                | Protein (mg/L)                  | 919.0 (332.8, 4434.8)              | 538.0 (187.0, 3652.0) | 0.582 |
|                                | Glucose (mmol/L)                | 4.3 (3.8, 5.0)                     | 4.2 (3.7, 5.8) | 0.927 |
|                                | Chlorides (mmol/L)              | 128.6 (121.9, 131.8)               | 123.1 (117.9, 125.4) | 0.072 |
| Pathogen                       | Positive                        | 6 (60.0)                           | 12 (63.2) | 1.000 |
|                                | Influenza virus                 | 4 (40.0)                           | 10 (52.6) | 0.700 |
| Cranial imaging                | Bilateral thalamus              | 10 (100)                           | 19 (100) | NA    |
|                                | Cerebral periventricular white matter | 7 (70.0)                  | 10 (52.6) | 0.449 |
|                                | Internal capsule                | 4 (40.0)                           | 11 (57.9) | 0.450 |
|                                | Brainstem                       | 5 (50.0)                           | 9 (47.4)  | 1.000 |
|                                | Cerebellar medulla              | 4 (40.0)                           | 5 (26.3)  | 0.675 |

Data are presented as \( n \) (%) or median (lower quartile, upper quartile). GCS, Glasgow coma scale score; ANE-SS, acute necrotizing encephalopathy severity score; CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cell; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransaminase; CSF, cerebrospinal fluid; NA, Not applicable.

**TABLE 3** Changes in the variables pre- and post-treatment in children with acute necrotizing encephalopathy

| Variables          | Plasma exchange group (n = 7) | Non-plasma exchange group (n = 11) | \( P \) |
|--------------------|-------------------------------|-----------------------------------|-------|
| CRP (mg/L)         | 13.1 (8.0, 26.3)              | 8.0 (3.1, 8.0)                    | 0.043 |
| PCT (ng/mL)        | 999.8 (5.5, 100.0)            | 91.5 (0.9, 44.3)                  | 0.028 |
| WBC (\( \times 10^9/L \)) | 996.1 (3.4, 7.8)            | 94.0 (3.1, 6.1)                   | 0.753 |
| PLT (\( \times 10^9/L \)) | 121.0 (47.0, 146.0)           | 74.0 (32.0, 117.0)                | 0.345 |
| ALT (U/L)          | 133.4 (63.9, 1631.5)          | 31.9 (27.4, 94.6)                 | 0.028 |
| AST (U/L)          | 282.4 (137.2, 1721.3)         | 50.5 (40.8, 61.4)                 | 0.046 |

Data are presented as median (lower quartile, upper quartile). CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cell; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransaminase.
TABLE 4 Treatments and outcomes in children with acute necrotizing encephalopathy in the two study groups

| Variables                        | Plasma exchange group (n = 10) | Non-plasma exchange group (n = 19) | P     |
|----------------------------------|-------------------------------|-----------------------------------|-------|
| **Treatments**                   |                               |                                   |       |
| Mechanical ventilation           | 9 (90.0)                      | 13 (68.4)                         | 0.367 |
| Duration of mechanical ventilation (hours) | 110.0 (42.5, 236.3)           | 38.0 (0, 99.0)                    | 0.106 |
| Antiviral therapy                | 10 (100)                      | 17 (89.5)                         | 0.532 |
| Steroids                         | 10 (100)                      | 18 (94.7)                         | 1.000 |
| Intravenous immunoglobulin       | 10 (100)                      | 18 (94.7)                         | 1.000 |
| **Outcomes**                     |                               |                                   |       |
| Duration of PICU stay (days)     | 10.1 (2.8, 19.1)              | 3.9 (2.0, 13.0)                   | 0.191 |
| Length of stay (days)            | 16.9 (3.5, 23.1)              | 8.0 (2.0, 19.0)                   | 0.278 |
| Died at discharge                | 0                             | 9 (47.4)                          | 0.011 |
| Died at the last follow-up*      | 3 (33.3)                      | 10 (58.8)                         | 0.411 |

Data are presented as n (%) or median (lower quartile, upper quartile). Three patients were lost to follow-up, including one patient in the plasma exchange group and two patients in the non-plasma exchange group.

comprising three patients (33.3%, 3/9) in the PLEX group and ten (58.8%, 10/17) in the non-PLEX group, but there was no significant difference between the two groups (P = 0.411) (Table 4). The two patients who received PLEX due to a poor response to immunomodulation therapy were alive at the last follow-up. On the basis of the PCPC and POPC, three patients (10.3%, 3/29) fully recovered, including one patient (10.0%, 1/10) in the PLEX group and two patients (10.5%, 2/19) in the non-PLEX group.

**DISCUSSION**

ANE is a rare and rapidly progressive encephalopathy with high mortality and disability rate. Song et al reported 30 children with ANE, and among them, 13 patients (43.3%) died and only three patients (10.0%) recovered. Okumura et al reported 34 patients with ANEC, and ten of them (29.4%) died, but four critically ill patients had been excluded. Bashiri et al reported 12 patients with ANEC, among whom early death occurred in 25%, and the others were left with neurological sequelae. In this study, nine patients (31.0%) with ANEC died at discharge, which increased to thirteen (50.0%) at the last follow-up, and three patients (10.3%) recovered. The outcomes varied in different studies, which may be related to the sample size, severity of the illness, and the length of the follow-up period. However, no standardized treatment schedule has been established for this catastrophic disease. It is necessary for pediatricians to find effective treatments to improve the prognosis of ANEC patients.

PLEX could be used to remove inflammatory factors from plasma, which is theoretically effective for ANEC. In this study, only eight patients had cytokine levels that were tested twice, and the testing time was different due to the retrospective nature of the study. Thus, we chose serum CRP and PCT as indicators of the inflammatory response. In children with confirmed influenza with neurological complications, the sensitivity and specificity of PCT > 4.25 ng/mL to predict ANE were 73.3% and 100.0%, respectively. Moreover, various proinflammatory cytokines had pronounced stimulatory effects on PCT expression, including interleukin (IL)-6 and tumor necrosis factor (TNF)-α, and elevated IL-6 and TNF-α were both found in serum and CSF of patients with ANE. In this study, CRP, PCT, ALT, and AST levels were significantly lower after PLEX, which indicated that PLEX could eliminate harmful substances from plasma in critical patients.

PLEX has been reported to treat ANEC, especially for patients with poor response to immunomodulation therapy. A patient with COVID-19 related ANE was treated with PLEX and survived at discharge, but required rehabilitation therapy after discharge. Among 13 patients with ANEC, three patients underwent five cycles of PLEX after a poor or no response to the initial immunomodulation treatment, and they were alive at discharge. Aksoy et al reported on nine children with ANE, and the six patients who received immunomodulation therapy and PLEX survived. Two of whom received PLEX when there was no clinical improvement with immunomodulation therapy. All the six patients who survived were left with mild to severe motor impairment, and the other three patients who received immunomodulation therapy died. Overall, PLEX may be a good method for treating ANEC, but there is not enough evidence to support its efficacy in ANEC patients. To increase the sample size, this multicenter study was conducted. Most patients received PLEX within 24 h after they were admitted to PICU, and two patients received PLEX due to a poor response to immunomodulation therapy. All of these patients were alive at discharge. Moreover, more patients died in the non-PLEX group than in the PLEX group at the last follow-up, which indicated that PLEX may improve the prognosis of ANEC.

Most patients with ANE had elevated liver enzymes, which is consistent with other studies. In this study, the AST level was significantly higher in the PLEX group than in the non-PLEX group on admission, which may suggest that clinically, PLEX is used selectively in children with higher liver enzyme levels. In the PLEX
group, ALT, and AST levels were significantly lower after PLEX. Therefore, the efficacy of PLEX for eliminating harmful substances in plasma can be observed. In addition to PLEX, most patients with ANE also received steroids and IVIG for immunomodulation in this study. The positive effects of steroid treatment may inhibit the inflammatory storm via suppressing cytokine levels and proinflammatory gene expression. IVIG may reduce the proliferation of T-cell and suppress the expression of various pro-inflammatory cytokines. The CRP level was significantly lower after treatment than before treatment in the non-PLEX group, which may be related to the immunomodulation treatment.

There are some limitations to this retrospective study. First, it is a non-randomized controlled trial, and the patients’ condition and the technical limitations may affect the application of PLEX. The sample size was still small because ANEC occurrence is rare. Second, laboratory examinations 3 days after treatment were not performed for all patients. Third, the change in cytokine levels pre- and post-PLEX were not investigated in this study. Finally, although the use of drugs was similar in both groups, the effect of combination medication could not be ruled out. It is necessary to increase the sample size and perform a prospective study on the treatment of ANEC in the future.

PLEX may reduce serum CRP and PCT levels and improve liver function in the short term. PLEX may improve the prognosis of ANEC, and further studies are needed to confirm the efficacy of PLEX for treating ANEC.

ACKNOWLEDGMENTS

We would like to thank all the families and individuals who participated in this study, and appreciate all the staffs in the PICU from the four centers.

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Mizuguchi M, Abe J, Mikkaichi K, Noma S, Yoshida K, Yamanaka T, et al. Acute necrotising encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry. 1995;58:555-561.
2. Hoshino A, Saitoh M, Oka A, Okumura A, Kubota M, Saito Y, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev. 2012;34:337-343.
3. Ichiyama T, Endo S, Kaneko M, Isumi H, Matsubara T, Furukawa S. Serum cytokine concentrations of influenza-associated acute necrotizing encephalopathy. Pediatr Int. 2003;45:734-736.
4. Ichiyama T, Isumi H, Ozawa H, Matsubara T, Morishima T, Furukawa S. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis. 2003;35:59-61.
5. Kansagra SM, Gallanté WB. Cytokine storm of acute necrotizing encephalopathy. Pediatr Neurol. 2011;45:400-402.
6. Neilson DE, Adams MD, Orr CM, Schelling DK, Eiben RM, Kerr DS, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009;84:44-51.
7. Shinohara M, Saitoh M, Takanashi J, Yamanouchi H, Kubota M, Goto T, et al. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev. 2011;33:512-517.
8. Shirai T, Fujii H, Ono M, Watanabe R, Shirota Y, Saito S, et al. A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy. J Neuroinflamm. 2013;10:128.
9. Bashiri FA, Al Johani S, Hamad MH, Kentab AY, Alwadei AH, Hundallah K, et al. Acute necrotizing encephalopathy of childhood: A multicenter experience in Saudi Arabia. Front Pediatr. 2020;8:526.
10. Okumura A, Mizuguchi M, Kidokoro H, Tanaka M, Abe S, Hosoya M, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev. 2009;31:221-227.
11. Song Y, Li S, Xiao W, Shen J, Ma W, Wang Q, et al. Influenza-associated encephalopathy and acute necrotizing encephalopathy in Children: A retrospective single-center study. Med Sci Monit. 2021;27:e928374.
12. Lee YJ, Hwang SK, Kwon S. Acute Necrotizing Encephalopathy in Children: a Long Way to Go. J Korean Med Sci. 2019;34:e143.
13. Chow CK, Ma C. Presentation and Outcome of Acute Necrotizing Encephalopathy of Childhood: A 10-Year Single-Center Retrospective Study From Hong Kong. J Child Neurol. 2020;35:674-680.
14. Mizuguchi M, Ichiyama T, Imataka G, Okumura A, Goto T, Sakuma H, et al. Guidelines for the diagnosis and treatment of acute encephalopathy in children. Brain Dev. 2021;43:2-31.
15. Virhammar J, Kumlien E, Fällmar D, Frithiof R, Jackmann AH, Hundallah K, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020;95:445-449.
16. Fong CY, Saw MT, Li L, Lim WK, Ong LC, Gan CS. Malaysian outcome of acute necrotising encephalopathy of childhood. Brain Dev. 2021;43:538-547.
17. Yamamoto H, Okumura A, Natsume J, Kojima S, Mizuguchi M. A severity score for acute necrotizing encephalopathy. Brain Dev. 2015;37:322-327.
18. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134:49-55.
19. Tabarki B, Thabet F, Al Shafi S, Al Adwani N, Chehab M, Al Shahwan S. Acute necrotizing encephalopathy associated with enterovirus infection. Brain Dev. 2013;35:454-457.
20. Daga Ruiz D, Fonseca San Miguel F, González de Molina FJ, Úbeda-Iglesias A, Navas Pérez A, Jannone Forés R. Plasmapheresis and other extracorporeal filtration techniques in critical patients. Med Intensiva. 2017;41:174-187.

21. Aksoy E, Öztöprak Ü, Çelik H, Özdemir FMA, Özkan M, Kayılkılıoğlu H, et al. Acute necrotizing encephalopathy of childhood: A single-center experience. Turk J Med Sci. 2021;51:706-715.

22. Wu X, Wu W, Pan W, Wu L, Liu K, Zhang HL. Acute necrotizing encephalopathy: an underrecognized clinicoradiologic disorder. Mediators Inflamm. 2015;2015:792578.

23. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther. 2011;9:807-822.

24. Aktas O, Waiczies S, Grie ger U, Wendling U, Zschenderlein R, Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol. 2001;114:160-167.

How to cite this article: Li K, Zhang T, Liu G, Jin P, Wang Y, Wang L, et al. Plasma exchange therapy for acute necrotizing encephalopathy of childhood. Pediatr Investig. 2021;5:99-105. https://doi.org/10.1002/ped4.12280